Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma

Patrick J. Stiff, Ivana Micallef, Auayporn P. Nademanee, Edward A. Stadtmauer, Richard Maziarz, Brian J. Bolwell, Gary Bridger, Sachin Marulkar, Frank J. Hsu, John F. DiPersio

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for patients with hematologic malignancies, yet the impact of transplanted CD34 + cell dose on clinical outcomes is unresolved. We conducted post hoc analyses of transplanted CD34 + cell dose and hematopoietic recovery following ASCT in 438 patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), using data from 2 multicenter phase 3 clinical studies that compared plerixafor plus granulocyte-colony stimulating factor (G-CSF) versus placebo plus G-CSF as stem cell mobilization regimens. Days to engraftment and the proportion of patients who reached predetermined blood count thresholds were compared across 3 CD34 + cell dose levels: 2-4 × 10 6 cells/kg, 4-6 × 10 6 cells/kg, and >6 × 10 6 cells/kg, regardless of mobilization treatment. Short-term neutrophil and platelet engraftment times were similar regardless of cell dose. A significant linear trend was observed between transplanted CD34 + cell dose and the proportion of patients with platelet count >150 × 10 9/L at 100 days (P <.001), 6 months (P = 026), and 12 months (P = 020) in patients with NHL, and at 100 days in patients with MM (P = 004). A linear trend was also observed between transplanted cell dose and the proportion of patients with platelet count >100 × 10 9/L at 100 days (P <.001) and 6 months (P = 023) in patients with NHL. A higher cell dose was associated with a lower percentage of NHL patients requiring red blood cell transfusions (P = 006). Our analyses confirm previous findings that transplanted CD34 + cell dose may be associated with better long-term platelet recovery after ASCT.

Original languageEnglish (US)
Pages (from-to)1146-1153
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Multiple Myeloma
Platelet Count
Non-Hodgkin's Lymphoma
Transplants
Hematopoietic Stem Cell Transplantation
Granulocyte Colony-Stimulating Factor
Blood Platelets
Peripheral Blood Stem Cells
Hematopoietic Stem Cell Mobilization
Erythrocyte Transfusion
Hematologic Neoplasms
Neutrophils
Placebos
Therapeutics

Keywords

  • Autologous peripheral blood stem cell transplantation
  • Cell dose
  • Platelet recovery
  • Plerixafor

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma. / Stiff, Patrick J.; Micallef, Ivana; Nademanee, Auayporn P.; Stadtmauer, Edward A.; Maziarz, Richard; Bolwell, Brian J.; Bridger, Gary; Marulkar, Sachin; Hsu, Frank J.; DiPersio, John F.

In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 8, 08.2011, p. 1146-1153.

Research output: Contribution to journalArticle

Stiff, Patrick J. ; Micallef, Ivana ; Nademanee, Auayporn P. ; Stadtmauer, Edward A. ; Maziarz, Richard ; Bolwell, Brian J. ; Bridger, Gary ; Marulkar, Sachin ; Hsu, Frank J. ; DiPersio, John F. / Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma. In: Biology of Blood and Marrow Transplantation. 2011 ; Vol. 17, No. 8. pp. 1146-1153.
@article{1304ead26dcf4e20a52df8441dcfe984,
title = "Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma",
abstract = "Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for patients with hematologic malignancies, yet the impact of transplanted CD34 + cell dose on clinical outcomes is unresolved. We conducted post hoc analyses of transplanted CD34 + cell dose and hematopoietic recovery following ASCT in 438 patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), using data from 2 multicenter phase 3 clinical studies that compared plerixafor plus granulocyte-colony stimulating factor (G-CSF) versus placebo plus G-CSF as stem cell mobilization regimens. Days to engraftment and the proportion of patients who reached predetermined blood count thresholds were compared across 3 CD34 + cell dose levels: 2-4 × 10 6 cells/kg, 4-6 × 10 6 cells/kg, and >6 × 10 6 cells/kg, regardless of mobilization treatment. Short-term neutrophil and platelet engraftment times were similar regardless of cell dose. A significant linear trend was observed between transplanted CD34 + cell dose and the proportion of patients with platelet count >150 × 10 9/L at 100 days (P <.001), 6 months (P = 026), and 12 months (P = 020) in patients with NHL, and at 100 days in patients with MM (P = 004). A linear trend was also observed between transplanted cell dose and the proportion of patients with platelet count >100 × 10 9/L at 100 days (P <.001) and 6 months (P = 023) in patients with NHL. A higher cell dose was associated with a lower percentage of NHL patients requiring red blood cell transfusions (P = 006). Our analyses confirm previous findings that transplanted CD34 + cell dose may be associated with better long-term platelet recovery after ASCT.",
keywords = "Autologous peripheral blood stem cell transplantation, Cell dose, Platelet recovery, Plerixafor",
author = "Stiff, {Patrick J.} and Ivana Micallef and Nademanee, {Auayporn P.} and Stadtmauer, {Edward A.} and Richard Maziarz and Bolwell, {Brian J.} and Gary Bridger and Sachin Marulkar and Hsu, {Frank J.} and DiPersio, {John F.}",
year = "2011",
month = "8",
doi = "10.1016/j.bbmt.2010.11.021",
language = "English (US)",
volume = "17",
pages = "1146--1153",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma

AU - Stiff, Patrick J.

AU - Micallef, Ivana

AU - Nademanee, Auayporn P.

AU - Stadtmauer, Edward A.

AU - Maziarz, Richard

AU - Bolwell, Brian J.

AU - Bridger, Gary

AU - Marulkar, Sachin

AU - Hsu, Frank J.

AU - DiPersio, John F.

PY - 2011/8

Y1 - 2011/8

N2 - Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for patients with hematologic malignancies, yet the impact of transplanted CD34 + cell dose on clinical outcomes is unresolved. We conducted post hoc analyses of transplanted CD34 + cell dose and hematopoietic recovery following ASCT in 438 patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), using data from 2 multicenter phase 3 clinical studies that compared plerixafor plus granulocyte-colony stimulating factor (G-CSF) versus placebo plus G-CSF as stem cell mobilization regimens. Days to engraftment and the proportion of patients who reached predetermined blood count thresholds were compared across 3 CD34 + cell dose levels: 2-4 × 10 6 cells/kg, 4-6 × 10 6 cells/kg, and >6 × 10 6 cells/kg, regardless of mobilization treatment. Short-term neutrophil and platelet engraftment times were similar regardless of cell dose. A significant linear trend was observed between transplanted CD34 + cell dose and the proportion of patients with platelet count >150 × 10 9/L at 100 days (P <.001), 6 months (P = 026), and 12 months (P = 020) in patients with NHL, and at 100 days in patients with MM (P = 004). A linear trend was also observed between transplanted cell dose and the proportion of patients with platelet count >100 × 10 9/L at 100 days (P <.001) and 6 months (P = 023) in patients with NHL. A higher cell dose was associated with a lower percentage of NHL patients requiring red blood cell transfusions (P = 006). Our analyses confirm previous findings that transplanted CD34 + cell dose may be associated with better long-term platelet recovery after ASCT.

AB - Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for patients with hematologic malignancies, yet the impact of transplanted CD34 + cell dose on clinical outcomes is unresolved. We conducted post hoc analyses of transplanted CD34 + cell dose and hematopoietic recovery following ASCT in 438 patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), using data from 2 multicenter phase 3 clinical studies that compared plerixafor plus granulocyte-colony stimulating factor (G-CSF) versus placebo plus G-CSF as stem cell mobilization regimens. Days to engraftment and the proportion of patients who reached predetermined blood count thresholds were compared across 3 CD34 + cell dose levels: 2-4 × 10 6 cells/kg, 4-6 × 10 6 cells/kg, and >6 × 10 6 cells/kg, regardless of mobilization treatment. Short-term neutrophil and platelet engraftment times were similar regardless of cell dose. A significant linear trend was observed between transplanted CD34 + cell dose and the proportion of patients with platelet count >150 × 10 9/L at 100 days (P <.001), 6 months (P = 026), and 12 months (P = 020) in patients with NHL, and at 100 days in patients with MM (P = 004). A linear trend was also observed between transplanted cell dose and the proportion of patients with platelet count >100 × 10 9/L at 100 days (P <.001) and 6 months (P = 023) in patients with NHL. A higher cell dose was associated with a lower percentage of NHL patients requiring red blood cell transfusions (P = 006). Our analyses confirm previous findings that transplanted CD34 + cell dose may be associated with better long-term platelet recovery after ASCT.

KW - Autologous peripheral blood stem cell transplantation

KW - Cell dose

KW - Platelet recovery

KW - Plerixafor

UR - http://www.scopus.com/inward/record.url?scp=79960216473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960216473&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.11.021

DO - 10.1016/j.bbmt.2010.11.021

M3 - Article

C2 - 21126595

AN - SCOPUS:79960216473

VL - 17

SP - 1146

EP - 1153

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -